Serine-Threonine Kinase Inhibitors Threonine-Tyrosine Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Heat Shock Protein Inhibitors EGFR Tyrosine Kinase Inhibitors | Melanoma | Cutaneous Melanoma | Solid Tumor |
---|---|---|---|
pembrolizumab | |||
nivolumab | |||
binimetinib + encorafenib | |||
encorafenib | |||
trametinib + dabrafenib + PDR001 | |||
trametinib + dabrafenib | |||
trametinib | |||
trametinib + dabrafenib + MCS110 | |||
pembrolizumab + trametinib + dabrafenib | |||
atezolizumab + vemurafenib + cobimetinib | |||
trametinib + dabrafenib + AT13387 | |||
vemurafenib | |||
BGB-283 | |||
vemurafenib + cobimetinib | |||
9-ING-41 | |||
pembrolizumab + vemurafenib + cobimetinib | |||
dabrafenib | |||
PD1 inhibitor + CTLA4 inhibitor | |||
Immunotherapy |